Prothena (NASDAQ:PRTA) posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.52) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.60) by $0.08, MarketWatch Earnings reports. The firm had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.20 million. Prothena had a negative return on equity of 33.45% and a negative net margin of 13,978.88%.
Prothena stock traded down $0.14 during midday trading on Friday, reaching $9.37. 1,931 shares of the stock traded hands, compared to its average volume of 309,075. Prothena has a 12-month low of $8.63 and a 12-month high of $15.91. The stock has a market capitalization of $377.12 million, a price-to-earnings ratio of -2.60 and a beta of 2.40. The company has a debt-to-equity ratio of 0.07, a current ratio of 27.85 and a quick ratio of 27.85.
Several analysts have issued reports on the company. Zacks Investment Research upgraded Prothena from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a report on Wednesday, May 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Prothena in a report on Thursday, May 16th. BidaskClub cut Prothena from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, ValuEngine upgraded Prothena from a “sell” rating to a “hold” rating in a report on Tuesday, April 23rd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. Prothena has a consensus rating of “Hold” and a consensus price target of $12.39.
TRADEMARK VIOLATION NOTICE: This piece was originally published by Rockland Register and is the sole property of of Rockland Register. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://rocklandregister.com/2019/05/31/prothena-prta-releases-earnings-results-beats-estimates-by-0-08-eps.html.
Prothena Company Profile
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis.
Featured Story: What is required to own or exchange cryptocurrency?
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.